Skip to main content
Clinical Trials/IRCT20200413047063N3
IRCT20200413047063N3
Recruiting
Phase 1

Safety of injection of placental mesenchymal stem cell derived exosomes for Treatment of resistant perianal fistula in Crohn's patients

Omid cell and tissue Company0 sites20 target enrollmentTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Crohn Patients with fistula.
Sponsor
Omid cell and tissue Company
Enrollment
20
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Omid cell and tissue Company

Eligibility Criteria

Inclusion Criteria

  • Patient with Crohn or other IBD disease, resistance to a 6 month period of treatment with anti TNF, without any success
  • Patient with Crohn or other IBD disease, resistance to a 6 month period of treatment with infliximab, without any success
  • Patient with Crohn or other IBD disease, resistance to a 6 month period of treatment with infliximab and anti TNF, without any success
  • Patient with Crohn or other IBD disease, resistance to a 6 month period of drug therapy and surgery, without any success

Exclusion Criteria

  • Patients with immunodeficiency disorders/disease
  • Patients with history of malignancy
  • Patient dissatisfaction
  • Patients in need of surgery
  • Severe co\-morbidities (e.g., renal failure, liver failure, etc.)
  • Cerebral Damage

Outcomes

Primary Outcomes

Not specified

Similar Trials